Company assumes responsibilities for joint supplement, offering “even broader support” for maintenance of orthopaedic health in dogs.
Novartis Animal Health has assumed marketing responsibilities for the joint health supplement Dasuquin in the United Kingdom and Ireland, offering vets “even broader support” for the maintenance of orthopaedic health in dogs.
According to the company, Dasuquin is an exclusive veterinary formulation developed to deliver advanced cartilage support in dogs. It contains a “unique” combination of glucosamine hydrochloride, chondroitin sulphate, avocado/soybean unsaponifiables and tea polyphenols, which, says Novartis, work synergistically to protect the cartilage, playing “an important role” in supporting and maintaining joint health.
Dasuquin is available in chewable tablets in 80-count containers and comes in two strengths:
- small-to-medium dogs weighing five-25kg; and
- large dogs weighing 25-50kg.
General manager for Novartis UK and Ireland Gaynor Hillier said Dasuquin is “a fitting addition” to the company’s overall orthopaedic health offering for vets and pet owners.
“Dasuquin brings vets and dog owners advanced joint health support with the next generation of the popular Cosequin family,” she said.
Dasuquin is available from Novartis Animal Health in the United Kingdom and Ireland from licensed veterinary wholesalers.
- For more information on Dasuquin and other Novartis products and services, contact your Novartis territory manager.